A fair chunk of Australia had the day off, keeping trade thin as weak US jobs data lifted the ASX and cooled Fed hike fears.
CSL will pay an upfront US$355 million ($515m) to co-develop an external drug candidate aimed at treating rare kidney and liver diseases.
Results from a US trial have strengthened ARX’s evidence base for Symphony in diabetic foot ulcers, achieving improved healing alongside standard care.
The submission comes just days after OIL lodged a separate 510(k) application for its InForm digital pathology device on October 2.
Barry FitzGerald is joined by founder and executive chairman Arvind Misra as the company looks towards its entry onto the ASX.
